Necrostatin-1 analogue with superior potency (IC50 = 206nM vs 494nM), selectivity and metabolic stability in blocking RIP1. Shows no off-target inhibition of indolamine-2,3-deoxygenase (IDO) in contrast to Necrostatin-1 (Nec-1). Showed higher activity in inhibiting necroptosis in Jurkat cells than Necrostatin-1 (EC50 = 210 nM vs. EC50 = 490 nM), no non-specific cytotoxicity at high concentrations (100 M) and reasonable pharmacokinetic characteristics when used in mice. Recommended for cellular and in vivo use over Necrostatin-1.5; Purity: > 98%; Molecular Weight: 277.71; Form/Appearance: powder, 25 mg